ACT Genomics

Is MSI Testing Using NGS Data Accurate?

US FDA approves treatment for cancers with high microsatellite instability (MSI-H) highlight the importance of MSI testing in cancer treatment ; more and more companies adopting to use NGS data for MSI assessment, and the biggest benefit of NGS-based MS

SG MSL Team of ACT Genomics 2020-10-13

Ovarian Cancer Patient: Ms. Chang

While fighting ovarian cancer for 18 years, Ms. Chang underwent several rounds of chemotherapy and surgery. At her last check-up, her cancer was found to have metastasized. She was at the point of accepting her fate when her attending doctor recommended genomic profiling, which led to a treatment recommendation that had not previously been considered.

ACTG 2020-12-24

Squamous Cell Skin Cancer Patient: Ms. Chen

The family members of 87-year-old Ms. Chen were reluctant that she be made to endure another surgery when her cancer relapsed owing to her age and effects of previous surgeries. Genomic profiling was then explored with her doctor to identify if she might be a candidate of immunotherapy. Fortunately, she is.

ACTG 2020-10-26

Phase 3 THOR study: Results of erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer with selective fibroblast growth factor receptor alterations

Currently, immune checkpoint inhibitors (ICIs) are widely used as first-line therapy for patients with metastatic urothelial carcinoma who are ineligible for platinum-based therapy or who have failed first-line platinum-based chemotherapy. However, only 30% of patients receive subsequent anti-cancer treatments after discontinuing ICI. Several genomic studies of metastatic urothelial carcinoma have shown FGFR2/3 alterations in 20% of patients, and erdafitinib has demonstrated clinical benefit in patients with disease progression after platinum-based chemotherapy.

2023-08-29

Phase 3 THOR study: Results of erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer with selective fibroblast growth factor receptor alterations

ORCHID Trial Shows Potential for Olaparib in Patients with Metastatic Renal Cell Carcinoma Carrying Mutations in BAP1 or Other DNA Repair Genes

In the interim analysis of the ORCHID study, metastatic renal cell carcinoma patients with BAP1 or other DNA repair gene mutations benefited from olaparib, which were presented at the 2023 Kidney Cancer Research Summit.

2023-08-29

ORCHID Trial Shows Potential for Olaparib in Patients with Metastatic Renal Cell Carcinoma Carrying Mutations in BAP1 or Other DNA Repair Genes

The First Treatment-switching by Monitoring Plasma ESR1 Mutations with circulating tumor DNA (ctDNA) Demonstrated Promising Clinical Benefit in the Phase III PADA-1 Study

Abstract: ASCO 2023 annual meeting updated with latest data from PADA-1 study, switching aromatase inhibitor (AI) to fulvestrant in case of rising ESR1 mutations by longitudinal ctDNA monitoring, showing progression-free survival1 (PFS1) and PFS2 significantly improved.

2023-08-29

The First Treatment-switching by Monitoring Plasma ESR1 Mutations with circulating tumor DNA (ctDNA) Demonstrated Promising Clinical Benefit in the Phase III PADA-1 Study

TALAPRO-2: Phase III study of talazoparib plus enzalutamide as first-line treatment for mCRPC patients harboring homologous recombination repair gene alterations

The TALAPRO-2 study demonstrated a statistically improvement of rPFS with talazoparib and enzalutamide combination in HRR gene-mutated mCRPC.

2023-07-27

TALAPRO-2: Phase III study of talazoparib plus enzalutamide as first-line treatment for mCRPC patients harboring homologous recombination repair gene alterations

VIDEOS

不同地區人種的基因特性對癌症治療有何重要性？

ACTG Blog

Is MSI Testing Using NGS Data Accurate?

Ovarian Cancer Patient: Ms. Chang

Squamous Cell Skin Cancer Patient: Ms. Chen

CLINICAL NEWS

Phase 3 THOR study: Results of erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer with selective fibroblast growth factor receptor alterations

ORCHID Trial Shows Potential for Olaparib in Patients with Metastatic Renal Cell Carcinoma Carrying Mutations in BAP1 or Other DNA Repair Genes

The First Treatment-switching by Monitoring Plasma ESR1 Mutations with circulating tumor DNA (ctDNA) Demonstrated Promising Clinical Benefit in the Phase III PADA-1 Study

TALAPRO-2: Phase III study of talazoparib plus enzalutamide as first-line treatment for mCRPC patients harboring homologous recombination repair gene alterations

VIDEOS

What are the benefits of genetic testing for cancer?

ACT Genomics received the Best Practice Award from Frost & Sullivan

REGULATORY

Drug Regulatory Status Jul 2023

Drug Regulatory Status Jun 2023

Drug Regulatory Status May 2023